Perspectives for a hepatitis C virus vaccine

Clinical and Diagnostic Virology

Volumn 10, Issue 2-3, 1998, Pages 181-185

  Abrignani, S ^a   Rosa, D ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Chronic infection; Hepatitis C; Neutralizing antibodies; NOB assay; Vaccine

Indexed keywords

HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; CHIMPANZEE; CONFERENCE PAPER; CYTOFLUOROMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; PRIORITY JOURNAL;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

ANIMALIA; HEPATITIS C VIRUS; PAN (APE); PAN TROGLODYTES;

EID: 0032527411     PISSN: 09280197     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0197(98)00028-2     Document Type: Conference Paper

References (17)

1. Abrignani S. Immune responses throughout HCV infection: HCV from the immune system point of view. Springer Semin Immunopathol. 19:1997;47-56.
2. Alberti A. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology. 26(S1):1997;137-142.
3. Botarelli P., Brunetto M.R., Minutello M.A., Calvo P., Unutmaz D., Weiner A.J., Choo Q.L., Shuster J.R., Kuo G., Bonino F., Houghton M., Abrignani S. T lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 104:1993;580-587.
4. Choo Q.-L., Kuo G., Ralston R., Weiner A.J., Chien D.Y., Van Nest G., Han J., Berger K., Thudium K., Kuo C., Kansopon J., McFarland J., Tabrizi A., Ching K., Moss B., Cummins L.B., Houghton M., Muchmore E. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 91:1994;1294-1298.
5. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1995;1006-1007.
6. Farci P., Alter H.J., Wong D., Miller R.H., Govindarajan S., Engle R., Shapiro M., Pureell R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA. 91:1994;7792-7796.
7. Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, editors. Virology. Philadelphia: Lippincott-Raven, 1996:1035-1058.
8. Knodell R.G., Conrad M.E., Ginsburg A.L., Bell C.J. Efficacy of prophylactic γ-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet. 1:1976;557-561.
9. Krawczynski K., Alter M.J., Tankersley D.L., Beach M., Robertson B.H., Lambert S., Kuo G., Spelbring J.E., Meeks E., Sinha S., Carson D.A. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis. 173:1996;822-828.
10. Kuo G., Choo Q.-L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., Miyamura T., Dienstag J.L., Alter M.J., Stevens C.E., Tegtmeier G.E., Bonino F., Colombo M., Lee W.S., Kuo C., Berger K., Shuster J.R., Overby L.R., Bradley D.W., Houghton M. An assay for circulating Ab to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-366.
11. Piazza M., Sagliocca L., Tosone G., Guadagnino V., Stazi M.A., Orlando R., Borgia G., Rosa D., Abrignani S., Palumbo F., Manzin A., Clementi M. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med. 157(14):1997;1537-1544.
12. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T lymphocyte response. Nat Med. 10:1996;1104-1108.
13. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., Dong C., Weiner A.J., Lau J.Y.N., Choo Q.L., Chien D., Pileri P., Houghton M., Abrignani S. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA. 93:1996;1759-1763.
14. Sanchez-Quijano A., Pienda J.A., Lissen E., Leal M., Diaz-Torres M.A., Garcia De Pesquera F., Rivera F., Castro R., Munoz J. Prevention of post-transfusion non A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet. 1:1988;1245-1249.
15. Van der Poel CL. Hepatitis C virus: epidemiology, transmission and prevention. In: Reesink H, editor. Hepatitis C virus: Current Studies in Hematology and Blood Transfusion, Basel: Karger, 1994:137-163.
16. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q-L., Houghton M., Han J.H. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 180:1991;842.
17. WHO, Weekly Epidemiological Record 1997:72:65-72.